Related Experiment Video
Updated: Jul 14, 2026
11:20
Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
Published on: March 29, 2018
Prostaglandin E(2) receptors in bone formation
M Li1, D D Thompson, V M Paralkar
1Pfizer Global Research and Development, Groton Laboratories, Mail Stop 8118W-208, Groton, CT, 06340, USA, mei.li@pfizer.com
International Orthopaedics
|June 27, 2007
Summary
Prostaglandin E2 (PGE2) has therapeutic potential for bone healing. Selective agonists targeting EP2 and EP4 receptors show promise for enhancing bone formation and repair in preclinical models.
Area of Science:
- Biomedical Science
- Pharmacology
- Orthopedics
Background:
- Prostaglandins, particularly Prostaglandin E2 (PGE2), exhibit diverse physiological effects.
- Systemic administration of PGE2 is limited by side effects, despite its roles in bone healing and formation.
- PGE2 mediates its actions via four G protein-coupled receptor subtypes: EP1, EP2, EP3, and EP4.
Purpose of the Study:
- To review the role of EP receptors in bone formation and healing.
- To focus on studies involving EP receptor knockout (KO) mice and EP2/EP4 selective agonist treatments.
Main Methods:
- Analysis of existing literature on EP receptor function in bone.
- Review of studies utilizing EP receptor knockout mouse models.
- Examination of data from animal models treated with EP2 or EP4 selective agonists.
Main Results:
- EP2 and EP4 receptors are crucial regulators of bone formation and resorption.
- Selective EP2 and EP4 receptor agonists stimulate bone formation and increase bone mass in animal models.
- Agonist administration accelerates fracture healing and bone defect repair in preclinical studies.
Conclusions:
- Targeting EP2 and EP4 receptors offers a promising therapeutic strategy for bone regeneration.
- Selective agonists may provide novel treatments for enhancing bone formation and repair in humans.
- Further research into EP receptor pathways could unlock new bone anabolic therapies.
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:17Hormones and Bone Tissue
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:40Bone Remodeling
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include: